1-5 of 5
Steven Middleton, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist

Benjamin Lanza, Giovanni Martinelli, Karen W.L. Yee, MD, Lori Jukofsky, Bernhard Reis, PhD, Steven Blotner, PhD, Mark W. Drummond, PhDMD, Norbert Vey, MD PhD, Karen Seiter, MD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Kevin R. Kelly, MD PhD, Margaret Kasner, MD, Michel Theron, PhD, Jeffrey M. Venstrom, Steven Middleton, PhD, Lin-Chi Chen, MD PhD, Nelson Kinnersley, Gwen Nichols, MD, William E. Pierceall, PhD
Journal: Blood
Blood (2016) 128 (22): 2843.
https://doi.org/10.1182/blood.V128.22.2843.2843
Published: 2016
Journal Articles

Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells

Bernhard Reis, PhD, Lori Jukofsky, Gong Chen, PhD, Giovanni Martinelli, Hua Zhong, PhD, Venus So, PhD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Mark W. Drummond, PhDMD, Sarit E. Assouline, MDMSc, Maneja Hashemyan, Michel Theron, PhD, Steven Blotner, PhD, Je-Hwan Lee, MD PhD, Margaret Kasner, MD, Sung-Soo Yoon, Ruediger Rueger, MD, Karen Seiter, MD, Steven Middleton, PhD, Kevin R. Kelly, MD, PhD, Norbert Vey, Karen W.L. Yee, MD, Gwen Nichols, MD, Lin-Chi Chen, MD PhD, William E. Pierceall, PhD
Journal: Blood
Blood (2015) 126 (23): 2580.
https://doi.org/10.1182/blood.V126.23.2580.2580
Published: 2015
Journal Articles

Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts)

Karen Yee, MD, Giovanni Martinelli, MD, Norbert Vey, MDPhD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Karen Seiter, MD, Sarit Assouline, MD MSc, Mark Drummond, MD PhD, Sung-Soo Yoon, MDPhD, Margaret Kasner, MD, Je-Hwan Lee, MD PhD, Kevin R. Kelly, MD PhD, Steven Blotner, PhD, Brian Higgins, Steven Middleton, PhD, Gwen Nichols, MD, Gong Chen, PhD, Hua Zhong, PhD, William E. Pierceall, PhD, Jianguo Zhi, PhD, Lin-Chi Chen, MD PhD
Journal: Blood
Blood (2014) 124 (21): 116.
https://doi.org/10.1182/blood.V124.21.116.116
Published: 2014
Journal Articles

Phase 1b Study Of The MDM2 Antagonist RG7112 In Combination With 2 Doses/Schedules Of Cytarabine

Karen Yee, MD, Giovanni Martinelli, MD, Sarit Assouline, MD, Margaret Kasner, MD, Norbert Vey, MD PhD, Kevin R. Kelly, MD, PhD, Mark W. Drummond, PhD, FRCPath, MB, CHB, Michael Dennis, FRCP, FRCPath, Karen Seiter, MD, Steven Blotner, PhD, Lori Jukofsky, Steven Middleton, PhD, Jianguo Zhi, PhD, Gong Chen, PhD, Hua Zhong, PhD, Gwen Nichols, MD
Journal: Blood
Blood (2013) 122 (21): 498.
https://doi.org/10.1182/blood.V122.21.498.498
Published: 2013
Journal Articles

Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia

Michael Andreeff, MD, PhD, Kevin R. Kelly, MD, Karen Yee, MD, Sarit Assouline, Roger Strair, MD, PhD, Leslie Popplewell, MD, David Bowen, Giovanni Martinelli, MD, Mark W. Drummond, PhD, FRCPath, MB, CHB, Paresh Vyas, MD, Mark Kirschbaum, MD, Swaminathan Padmanabhan Iyer, MD, Kensuke Kojima, MD, PhD, David Geho, MD, Steven Blotner, PhD, Suzanne Cheng, PhD, Lyubomir Vassilev, PhD, Meichun Ding, PhD, Jianguo Zhi, PhD, Steven Middleton, PhD, Gwen Nichols, MD
Journal: Blood
Blood (2012) 120 (21): 675.
https://doi.org/10.1182/blood.V120.21.675.675
Published: 2012